EUnetHTA Joint Action 3 (2016-2021)

Home  /  EUnetHTA Joint Action 3 (2016-2021)

On 6 Dec 2019, Celgene officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for enasidenib. Since no CHMP opinion will be granted at this stage, EUnetHTA

EUnetHTA recently started a new Collaborative Assessment of different surgical methods to treat morbid obesity  To find out about participation, please read more here. Input submissions will be received through EOB, 21st February, 2020 EUnetHTA deems patient input very important in the production of

The aim of this methodological guideline is to provide an up-to-date and transparent overview of the whole information retrieval process for Systematic reviews and HTAs on clinical effectiveness. In particular, the requirements presented in this methodological guideline aim to provide orientation